Isis Pharmaceuticals To Receive $1.1 Million From Alnylam

          Isis Pharmaceuticals To Receive $1.1 Million From Alnylam

PR Newswire

CARLSBAD, Calif., Oct. 23, 2012

CARLSBAD, Calif., Oct. 23, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
(NASDAQ: ISIS) announced today that it will receive $1.1 million from Alnylam
Pharmaceuticals, Inc. (NASDAQ: ALNY) as its portion of the upfront fees in
Alnylam's recently announced collaboration with Genzyme. In addition, Isis
has the potential to receive royalty payments and a portion of future
milestone payments. Already this year, Isis has earned $2.7 million from
Alnylam as a result of Alnylam's licenses that were supported by Isis'
patents, further emphasizing the value of Isis' innovation and the leadership
role Isis has played in the field of RNA-based technology.

"We have a broad and valuable patent estate built upon our innovations and
discoveries related to RNA-based technologies that provides us with extensive
protection for our drugs and our technologies. Our business strategy
maximizes the value of these innovations by granting partners access to our
technology for uses that are outside our key areas of focus. Using this
strategy, we have been able to generate more than $400 million from the sale
and licensing of our intellectual property," said B. Lynne Parshall, chief
operating officer and chief financial officer at Isis.

Isis is the leading company in RNA-based technology and owns or controls more
than 1,500 issued patents. As such, Isis holds patents for numerous
applications of antisense technology, including RNAi, and for novel targets,
such as microRNAs being developed by Regulus, which was co-founded by Isis and
Alnylam. In 2004, Isis and Alnylam entered into a strategic relationship in
which Alnylam obtained an exclusive license to Isis' intellectual property for
double-stranded oligonucleotide therapeutics that mediate RNAi. In return,
Isis received an upfront payment and financial participation in future
transactions supported by Isis' patents.

Isis is exploiting its leadership position in antisense technology to discover
and develop novel drugs for its product pipeline and for its partners. Isis'
broad pipeline consists of 25 drugs to treat a wide variety of diseases with
an emphasis on cardiovascular, metabolic, severe and rare diseases, and
cancer. Isis' partner, Genzyme, plans to commercialize Isis' lead product,
KYNAMRO™, following regulatory approval. Isis' patents provide strong and
extensive protection for its drugs and technology. Additional information
about Isis is available at

This press release includes forward-looking statements regarding Isis
Pharmaceuticals' business, its intellectual property estate, and the
therapeutic and commercial potential of Isis' products and technologies. Any
statement describing Isis' goals, expectations, financial or other
projections, intentions or beliefs, including the planned commercialization of
KYNAMRO, is a forward-looking statement and should be considered an at-risk
statement. Such statements are subject to certain risks and uncertainties,
particularly those inherent in the process of discovering, developing and
commercializing drugs that are safe and effective for use as human
therapeutics, and in the endeavor of building a business around such drugs.
Isis' forward-looking statements also involve assumptions that, if they never
materialize or prove correct, could cause its results to differ materially
from those expressed or implied by such forward-looking statements. Although
Isis' forward-looking statements reflect the good faith judgment of its
management, these statements are based only on facts and factors currently
known by Isis. As a result, you are cautioned not to rely on these
forward-looking statements. These and other risks concerning Isis' programs
are described in additional detail in Isis' annual report on Form 10-K for the
year ended December 31, 2011 and its most recent quarterly report on Form
10-Q, which are on file with the SEC. Copies of these and other documents are
available from the Company.

In this press release, unless the context requires otherwise, "Isis,"
"Company," "we," "our," and "us" refers to Isis Pharmaceuticals.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.
KYNAMRO™ is a trademark of Genzyme Corporation.

SOURCE Isis Pharmaceuticals, Inc.

Contact: D. Wade Walke, Ph.D., Executive Director, Corporate Communications
and Investor Relations, +1-760-603-2741, or Amy Blackley, Ph.D., Associate
Director, Corporate Communications, +1-760-603-2772
Press spacebar to pause and continue. Press esc to stop.